European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. PRME

Go back to European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
(AMEX: MKKGY) Delayed: 30.86 +0.22 (0.72%)
Previous Close $30.64    52 Week High $ 
Open $30.84    52 Week Low $ 
Day High $30.98    P/E N/A 
Day Low $30.71    EPS $ 
Volume 36,187       

Merck & Co. (NYSE: MRK) Delayed: 148.78 +0.80 (0.54%)
Previous Close $147.98    52 Week High $65.46 
Open $148.06    52 Week Low $47.97 
Day High $149.98    P/E 101.21 
Day Low $147.48    EPS $1.47 
Volume 8,290,254       

Pfizer Inc. (NYSE: PFE) Delayed: 28.67 +0.26 (0.92%)
Previous Close $28.41    52 Week High $37.39 
Open $28.45    52 Week Low $28.25 
Day High $28.69    P/E 17.38 
Day Low $28.17    EPS $1.65 
Volume 27,761,324